TABLE 3.
Proteins against which CLR01 has been tested and the main related diseases
| Protein/mutant | Inhibition of aggregation | Inhibition of toxicity | Associated disease |
|---|---|---|---|
| Aβ40, Aβ42 | √ | √ | Alzheimer’s disease |
| Tau | √ | √ | Tauopathies |
| α-Synuclein | √ | √ | Synucleinopathies |
| IAPP | √ | √ | Type 2 diabetes |
| Calcitonin | √ | √ | Medullary Carcinoma of the thyroid |
| Insulin | √ | √ | Injection-related amyloidosis |
| β2-Microglobulin | √ | √ | Dialysis-related amyloidosis |
| TTR | √ | √ | Senile systemic amyloidosis, familial amyloid polyneuropathy, familial amyloid cardiomyopathy |
| SOD1 | √ | √ | ALS |
| IgG light chain | √ | NA* | Light-chain amyloidosis |
| TDP43 | √ | NA* | ALS, FTD |
| C9ORF72 RAN translation products containing Arg | √ | √ | ALS, others |
| SEVI | √ | √ | HIV infection |
| P53 | √ | √ | Cancer |
| Huntingtin | √ | √ | Huntington’s disease |
| PMSα1 | √ | √ | Bacterial biofilm |
| Ataxin 3 | √ | √ | Spinocerebellar ataxia type 3 |
| αB-Crystallin | √ | √ | Desmin-related cardiomyopathy |
*NA – not available.